Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment.

Grande E, Harvey RD, You B, Feliu Batlle J, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M, Vishwanathan K.

J Pharmacol Exp Ther. 2019 Mar 14. pii: jpet.118.255919. doi: 10.1124/jpet.118.255919. [Epub ahead of print]

2.

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.

Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD.

Br J Clin Pharmacol. 2019 Mar 7. doi: 10.1111/bcp.13915. [Epub ahead of print]

PMID:
30845347
3.

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB.

Am J Clin Oncol. 2019 Feb 15. doi: 10.1097/COC.0000000000000524. [Epub ahead of print]

PMID:
30789414
4.

Managing Drug Interactions With Oral Anticancer Agents: Signals, Noise, and Echoes.

Harvey RD.

J Oncol Pract. 2019 Feb;15(2):91-92. doi: 10.1200/JOP.18.00721. No abstract available.

PMID:
30763201
5.

Reply to Tumor-associated macrophages: "Good cop-bad cop".

Bilen MA, Kissick HT, Harvey RD.

Cancer. 2019 Feb 12. doi: 10.1002/cncr.32015. [Epub ahead of print] No abstract available.

PMID:
30748009
6.

Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.

Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA.

Invest New Drugs. 2019 Feb 6. doi: 10.1007/s10637-019-00736-0. [Epub ahead of print]

PMID:
30725388
7.

Academic oncology clinicians' understanding of biosimilars and information needed before prescribing.

Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD.

Ther Adv Med Oncol. 2019 Jan 6;11:1758835918818335. doi: 10.1177/1758835918818335. eCollection 2019.

8.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S.

Blood Cancer J. 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8.

9.

The pH-dependence of lipid-mediated antimicrobial peptide resistance in a model staphylococcal plasma membrane: A two-for-one mechanism of epithelial defence circumvention.

Rehal R, Gaffney PRJ, Hubbard ATM, Barker RD, Harvey RD.

Eur J Pharm Sci. 2019 Feb 1;128:43-53. doi: 10.1016/j.ejps.2018.11.017. Epub 2018 Nov 22.

PMID:
30471412
10.

Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM.

Br J Clin Pharmacol. 2019 Mar;85(3):530-539. doi: 10.1111/bcp.13817. Epub 2018 Dec 25.

PMID:
30428505
11.

Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization: Evidence for keratinocyte invasion as a mechanism of biocide evasion.

Marbach H, Vizcay-Barrena G, Memarzadeh K, Otter JA, Pathak S, Allaker RP, Harvey RD, Edgeworth JD.

J Infect. 2019 Feb;78(2):119-126. doi: 10.1016/j.jinf.2018.10.007. Epub 2018 Oct 24.

PMID:
30367885
12.

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.

Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD.

Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17.

PMID:
30329148
13.

Diminishing biofilm resistance to antimicrobial nanomaterials through electrolyte screening of electrostatic interactions.

Harper RA, Carpenter GH, Proctor GB, Harvey RD, Gambogi RJ, Geonnotti AR, Hider R, Jones SA.

Colloids Surf B Biointerfaces. 2019 Jan 1;173:392-399. doi: 10.1016/j.colsurfb.2018.09.018. Epub 2018 Sep 12.

14.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Chehab S, Zhang C, Panjic EH, Chen Z, Kaufman JL, Lonial S, Nooka A, Harvey RD.

Cancer. 2018 Nov 15;124(22):4358-4365. doi: 10.1002/cncr.31746. Epub 2018 Oct 10.

PMID:
30303526
15.

Design and development of a biorelevant simulated human lung fluid.

Hassoun M, Royall PG, Parry M, Harvey RD, Forbes B.

J Drug Deliv Sci Technol. 2018 Oct;47:485-491. doi: 10.1016/j.jddst.2018.08.006.

16.

Accelerating anticancer drug development - opportunities and trade-offs.

Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL.

Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Review.

PMID:
30275514
17.

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K.

Br J Clin Pharmacol. 2018 Dec;84(12):2877-2888. doi: 10.1111/bcp.13753. Epub 2018 Oct 10.

PMID:
30171779
18.

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.

Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2019 Apr;58(4):431-449. doi: 10.1007/s40262-018-0702-1. Review.

19.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD.

N Engl J Med. 2018 Aug 16;379(7):694-695. doi: 10.1056/NEJMc1808348. No abstract available.

PMID:
30110587
20.

Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.

Moore DC, Arnall JR, Harvey RD.

J Oncol Pharm Pract. 2019 Apr;25(3):613-622. doi: 10.1177/1078155218788706. Epub 2018 Jul 31.

PMID:
30060709
21.

Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.

Owonikoko TK, Busari AK, Kim S, Chen Z, Akintayo A, Lewis C, Carthon BC, Alese OB, El-Rayes BF, Ramalingam SS, Harvey RD.

Oncology. 2018;95(3):138-146. doi: 10.1159/000488763. Epub 2018 Jun 18.

PMID:
29913438
22.

Reply to S.D. Lucio.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Jul 10;36(20):2127. doi: 10.1200/JCO.2018.79.1780. Epub 2018 May 30. No abstract available.

PMID:
29847292
23.

A combined FTIR and DSC study on the bilayer-stabilising effect of electrostatic interactions in ion paired lipids.

Schmid M, Wölk C, Giselbrecht J, Chan KLA, Harvey RD.

Colloids Surf B Biointerfaces. 2018 May 17;169:298-304. doi: 10.1016/j.colsurfb.2018.05.031. [Epub ahead of print]

PMID:
29793092
24.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Lyman GH, Zon R, Harvey RD, Schilsky RL.

N Engl J Med. 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125. No abstract available.

PMID:
29791832
25.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.

PMID:
29781056
26.

Compartmentalized cAMP Signaling Associated With Lipid Raft and Non-raft Membrane Domains in Adult Ventricular Myocytes.

Agarwal SR, Gratwohl J, Cozad M, Yang PC, Clancy CE, Harvey RD.

Front Pharmacol. 2018 Apr 23;9:332. doi: 10.3389/fphar.2018.00332. eCollection 2018.

27.

Glycerol Solvates DPPC Headgroups and Localizes in the Interfacial Regions of Model Pulmonary Interfaces Altering Bilayer Structure.

Terakosolphan W, Trick JL, Royall PG, Rogers SE, Lamberti O, Lorenz CD, Forbes B, Harvey RD.

Langmuir. 2018 Jun 12;34(23):6941-6954. doi: 10.1021/acs.langmuir.8b00866. Epub 2018 May 30.

PMID:
29738253
28.

Influence of the Surfactant Structure on Photoluminescent π-Conjugated Polymer Nanoparticles: Interfacial Properties and Protein Binding.

Urbano L, Clifton L, Ku HK, Kendall-Troughton H, Vandera KA, Matarese BFE, Abelha T, Li P, Desai T, Dreiss CA, Barker RD, Green MA, Dailey LA, Harvey RD.

Langmuir. 2018 May 29;34(21):6125-6137. doi: 10.1021/acs.langmuir.8b00561. Epub 2018 May 17.

PMID:
29726688
29.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

PMID:
29590007
30.

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL.

J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14.

PMID:
29443651
31.

Soft, adhesive (+) alpha tocopherol phosphate planar bilayers that control oral biofilm growth through a substantive antimicrobial effect.

Harper RA, Saleh MM, Carpenter G, Abbate V, Proctor G, Harvey RD, Gambogi RJ, Geonnotti A, Hider R, Jones SA.

Nanomedicine. 2018 Oct;14(7):2307-2316. doi: 10.1016/j.nano.2017.12.024. Epub 2018 Feb 2.

32.

Intranasal Ketamine and Its Potential Role in Cancer-Related Pain.

Singh V, Gillespie TW, Harvey RD.

Pharmacotherapy. 2018 Mar;38(3):390-401. doi: 10.1002/phar.2090. Epub 2018 Feb 23. Review.

PMID:
29396996
33.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.

Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD.

Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23.

PMID:
29381826
34.

cAMP Signaling Compartmentation: Adenylyl Cyclases as Anchors of Dynamic Signaling Complexes.

Johnstone TB, Agarwal SR, Harvey RD, Ostrom RS.

Mol Pharmacol. 2018 Apr;93(4):270-276. doi: 10.1124/mol.117.110825. Epub 2017 Dec 7.

PMID:
29217670
35.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

36.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.

Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L.

J Clin Oncol. 2017 Nov 20;35(33):3753-3759. doi: 10.1200/JCO.2017.74.4102. Epub 2017 Oct 2.

PMID:
28968172
37.

Science of Biosimilars.

Harvey RD.

J Oncol Pract. 2017 Sep;13(9_suppl):17s-23s. doi: 10.1200/JOP.2017.026062. Review.

PMID:
28898589
38.

Comparing the action of HT61 and chlorhexidine on natural and model Staphylococcus aureus membranes.

Hubbard AT, Coates AR, Harvey RD.

J Antibiot (Tokyo). 2017 Oct;70(10):1020-1025. doi: 10.1038/ja.2017.90. Epub 2017 Aug 2.

PMID:
28765589
39.

The influence of mild acidity on lysyl-phosphatidylglycerol biosynthesis and lipid membrane physico-chemical properties in methicillin-resistant Staphylococcus aureus.

Rehal RP, Marbach H, Hubbard ATM, Sacranie AA, Sebastiani F, Fragneto G, Harvey RD.

Chem Phys Lipids. 2017 Aug;206:60-70. doi: 10.1016/j.chemphyslip.2017.06.007. Epub 2017 Jun 23.

PMID:
28648851
40.

Compartmentalized cAMP responses to prostaglandin EP2 receptor activation in human airway smooth muscle cells.

Agarwal SR, Miyashiro K, Latt H, Ostrom RS, Harvey RD.

Br J Pharmacol. 2017 Aug;174(16):2784-2796. doi: 10.1111/bph.13904. Epub 2017 Jul 12.

41.

A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias.

Yang PC, Perissinotti LL, López-Redondo F, Wang Y, DeMarco KR, Jeng MT, Vorobyov I, Harvey RD, Kurokawa J, Noskov SY, Clancy CE.

J Physiol. 2017 Jul 15;595(14):4695-4723. doi: 10.1113/JP273142. Epub 2017 Jun 14.

42.

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4.

43.

Mechanism of Action of a Membrane-Active Quinoline-Based Antimicrobial on Natural and Model Bacterial Membranes.

Hubbard AT, Barker R, Rehal R, Vandera KA, Harvey RD, Coates AR.

Biochemistry. 2017 Feb 28;56(8):1163-1174. doi: 10.1021/acs.biochem.6b01135. Epub 2017 Feb 13.

PMID:
28156093
44.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
45.

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

Beardslee TJ, Harvey RD.

Cancer. 2016 Nov 15;122(22):3424-3427. doi: 10.1002/cncr.30273. Epub 2016 Aug 15. No abstract available.

46.

Preventing and Managing Toxicities of High-Dose Methotrexate.

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD.

Oncologist. 2016 Dec;21(12):1471-1482. Epub 2016 Aug 5. Review.

47.

Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Mita MM, Nemunaitis J, Grilley-Olson J, El-Rayes B, Bekaii-Saab T, Harvey RD, Marshall J, Zhang X, Strout V.

Target Oncol. 2016 Dec;11(6):807-814.

PMID:
27457707
48.

A Computational Modeling and Simulation Approach to Investigate Mechanisms of Subcellular cAMP Compartmentation.

Yang PC, Boras BW, Jeng MT, Docken SS, Lewis TJ, McCulloch AD, Harvey RD, Clancy CE.

PLoS Comput Biol. 2016 Jul 13;12(7):e1005005. doi: 10.1371/journal.pcbi.1005005. eCollection 2016 Jul.

49.

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A.

Br J Haematol. 2016 Sep;174(5):748-59. doi: 10.1111/bjh.14125. Epub 2016 May 16.

50.

Calcium and Cancer: Of Evil Humors and Innocent Bystanders.

Harvey RD.

J Oncol Pract. 2016 May;12(5):433-4. doi: 10.1200/JOP.2016.012385. No abstract available.

PMID:
27170691

Supplemental Content

Loading ...
Support Center